Pharmicell non-registered executive Jeong Sun-ung acquired 668 common shares on June 16, 2026 through an employee stock ownership plan deposit, increasing his holdings from 3,746 to 4,414 shares.
This represents a negligible 0.00% change relative to total outstanding shares of 60,004,014, resulting in no meaningful dilution impact on existing shareholders.
The filing is a routine disclosure of executive shareholding change and does not involve corporate capital allocation or dividend policy.
[AI Summary]Pharmicell executive Jeong Sun-ung purchased 668 shares via employee stock plan. At 0.00% of total shares, there is zero dilutive effect on shareholder value. Market impact is neutral.
KOSPI Filing Information
Report on Ownership of Specific Securities by Executives and Major Shareholders